Quick Takeaways: Why It Matters? Boehringer Ingelheim’s purchase of Evax gives it a promising new way to treat common horse allergies with longer‑lasting vaccines instead of short‑term symptom relief, which could mean fewer vet visits and better outcomes for owners. If the approach works a...
Quick Takeaways: Why It Matters? With 138 horses across eight practices showing significantly better outcomes and nearly triple the odds of returning to prior performance, the data should help veterinarians justify using equicenta CTM as a convenient, regenerative alternative to harvesting...
